Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity - 30/03/13
![](/templates/common/images/entites/lowast.gif)
![](/templates/common/images/entites/lowast.gif)
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/lowast.gif)
Abstract |
Background |
Asthma is defined as a chronic inflammatory disease of the airways; however, the underlying physiologic and immunologic processes are not fully understood.
Objective |
The aim of this study was to determine whether TH9 cells develop in vivo in a model of chronic airway hyperreactivity (AHR) and what factors control this development.
Method |
We have developed a novel chronic allergen exposure model using the clinically relevant antigen Aspergillus fumigatus to determine the time kinetics of TH9 development in vivo.
Results |
TH9 cells were detectable in the lungs after chronic allergen exposure. The number of TH9 cells directly correlated with the severity of AHR, and anti–IL-9 treatment decreased airway inflammation. Moreover, we have identified programmed cell death ligand (PD-L) 2 as a negative regulator of TH9 cell differentiation. Lack of PD-L2 was associated with significantly increased TGF-β and IL-1⍺ levels in the lungs, enhanced pulmonary TH9 differentiation, and higher morbidity in the sensitized mice.
Conclusion |
Our findings suggest that PD-L2 plays a pivotal role in the regulation of TH9 cell development in chronic AHR, providing novel strategies for modulating adaptive immunity during chronic allergic responses.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, chronic airway hyperreactivity, Aspergillus fumigatus, TH9, costimulation, programmed cell death ligand 2, TGF-β
Abbreviations used : AHR, Cdyn, DC, IRF4, LN, OVA, PD-L, RL, STAT6, Teff, Treg, WT
Plan
Supported by the National Institutes of Health Public Health Service Grant R01 AI066020 (to O.A.), the American Lung Association Fellowship (to V.L.), and the Fonds National de la Recherche Scientifique Médicale de Belgique (to J.V.S.). |
|
Disclosure of potential conflict of interest: H. Maazi, B. Khoo, S. Geryak, J. Lam, and O. Akbari have received grants from the National Institutes of Health. J. Van Snick has received grants from Fonds National de la Recherche Scientifique Medicale de Belgique. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 131 - N° 4
P. 1048 - avril 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?